Jane Chung, R.Ph., has served as the Chief Executive Officer and a member of the Board of Directors of Sutro since March 2025, drawing on more than 20 years of pharmaceutical and biotechnology leadership experience. Prior to her appointment as CEO, Jane served as Sutro’s President and Chief Operating Officer, and previously as Chief Commercial Officer.
Before joining Sutro, Jane held several leadership roles at AstraZeneca, including President and General Manager of AstraZeneca Canada, Vice President of Sales and Marketing of U.S. lmmuno-Oncology, and Senior Commercial Business Director. Earlier, she served as a Regional Sales Director and Director of Sales Productivity and Effectiveness for Onyx Pharmaceuticals Inc., and held several commercial roles of increasing responsibility at Genentech, Inc., including Commercial Operations Manager, Division Manager and Senior Marketing Manager.
In addition, Jane has also served on the Board of Directors of Viracta Therapeutics, Inc., as well as on several nonprofit boards across science, education, and community development. She holds a B.A. from Columbia University, New York, and B.S. in Pharmacy from St. John’s University, New York.
What is Jane Chung's net worth?
The estimated net worth of Jane Chung is at least $421.99 thousand as of October 15th, 2025. Ms. Chung owns 12,285 shares of Sutro Biopharma stock worth more than $421,990 as of April 22nd. This net worth approximation does not reflect any other investments that Ms. Chung may own. Learn More about Jane Chung's net worth.
How do I contact Jane Chung?
Has Jane Chung been buying or selling shares of Sutro Biopharma?
Jane Chung has not been actively trading shares of Sutro Biopharma during the last quarter. Most recently, on Wednesday, October 15th, Jane Chung bought 1,250 shares of Sutro Biopharma stock. The stock was acquired at an average cost of $8.00 per share, with a total value of $10,000.00. Following the completion of the transaction, the chief executive officer now directly owns 12,285 shares of the company's stock, valued at $98,280. Learn More on Jane Chung's trading history.
Who are Sutro Biopharma's active insiders?
Are insiders buying or selling shares of Sutro Biopharma?
During the last year, Sutro Biopharma insiders bought shares 5 times. They purchased a total of 11,175 shares worth more than $89,597.50. The most recent insider tranaction occured on October, 15th when insider Hans-Peter Gerber bought 1,700 shares worth more than $13,600.00. Insiders at Sutro Biopharma own 5.9% of the company.
Learn More about insider trades at Sutro Biopharma. Information on this page was last updated on 10/15/2025.
